Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management

• Status: Completed
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Baghdad
• Treatments: Hydroxychloroquine; Ivermectin

Criteria

Inclusion Criteria:

-1. Patients with age above 18 years and any gender with definite Dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria.

2. Understands and agrees to comply with planned study procedures.

Exclusion Criteria:

1. Patients with hypersensitivity or severe adverse effects to Ivermectin

2. Renal impairment

3. Hepatic impairment.

4. Pregnancy or a desire to become pregnant (drug considered pregnancy category c)

5. Breast feeding.

6. Patient with covid 19 positive and mild no pneumonia

7. Children under the age of five or those who weigh less than 15 kilograms